MRI Study Reveals Brain Differences in Patients with Migraine, Offering Hope for Better Diagnostics and Treatment
Posted on April 18 2024,

A recent study published in the journal Neurology has found interesting observations on the brain structure of people with migraine. The study compared MRI scans of 296 migraine patients to 155 healthy controls, analyzing cortical surface area, thickness, and volume.
The researchers found that migraine patients, especially those with chronic migraine, had reduced cortical surface area in the left anterior insula, a region involved in pain processing. They also discovered increased surface area in the right caudal anterior cingulate cortex (ACC) in chronic migraine, which correlated with monthly headache frequency. Furthermore, migraine without aura was associated with greater right caudal ACC surface area compared to controls.
No significant differences in cortical thickness or volume were found between migraine and control groups.
The study's findings have important implications for people with migraine. The distinct brain signatures observed in different migraine subtypes suggest that personalized diagnostics and therapies may be possible in the future.
The association between medication overuse/adaptation headache and brain structure changes also highlights the need for effective preventive treatments.
Finally, this is also further evidence that migraine is not “just in your head” as some therapy people we recently talked about like to claim. It is not fear-based, but real, anatomical, and functional changes occurring in the nervous system, including the brain.
Thu, Apr 24, 25
Clinical Predictors for Efficacy of Erenumab (Aimovig) for Migraine
Discover key predictors of Aimovig (erenumab) response in migraine patients. This REFORM study reveals which patients benefit most from CGRP therapy and why timing matters. Evidence-based insights for better treatment...
Read MoreWed, Apr 23, 25
Effectiveness and Tolerability of Atogepant (Qulipta) in the Prevention of Migraine
STAR study shows atogepant (Qulipta) effectively reduces migraine days by 56.6% in real-world clinical practice, even for patients with previous treatment failures. Learn about this breakthrough.
Read MoreWed, Apr 23, 25
Impact of Visual Stimulus Complexity on Associative Learning in Migraine Patients
Groundbreaking research reveals how migraine patients process visual information differently. This 2025 study found that migraine patients take longer to process simple visual stimuli compared to complex images, which is...
Read More